Since angiogenesis is closely related to tumor metastasis, it can be a novel therapeutic strategy to combine compound C108 with antiangiogenic agents or antibodies against HDGF in the treatment of metastatic ESCC, which may achieve better treatment effects. Here, HDGF is linked to esophageal squamous cell carcinoma.